Endurance Wealth Management Inc. Grows Position in Bristol-Myers Squibb Co (NYSE:BMY)

Endurance Wealth Management Inc. boosted its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 41.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 4,474 shares of the biopharmaceutical company’s stock after buying an additional 1,301 shares during the quarter. Endurance Wealth Management Inc.’s holdings in Bristol-Myers Squibb were worth $288,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in BMY. Garrett Wealth Advisory Group LLC purchased a new stake in Bristol-Myers Squibb in the 3rd quarter valued at $26,000. Lenox Wealth Advisors LLC raised its position in Bristol-Myers Squibb by 555.7% in the 3rd quarter. Lenox Wealth Advisors LLC now owns 636 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 539 shares during the last quarter. Financial Gravity Wealth Inc. raised its position in Bristol-Myers Squibb by 101.2% in the 3rd quarter. Financial Gravity Wealth Inc. now owns 650 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 327 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. grew its stake in Bristol-Myers Squibb by 52.9% in the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 665 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 230 shares during the period. Finally, 1 North Wealth Services LLC bought a new position in Bristol-Myers Squibb in the 3rd quarter valued at $41,000. 83.02% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE:BMY opened at $66.44 on Wednesday. The company has a debt-to-equity ratio of 1.37, a current ratio of 3.83 and a quick ratio of 3.72. The company has a market capitalization of $106.28 billion, a PE ratio of 16.69, a price-to-earnings-growth ratio of 0.84 and a beta of 0.73. Bristol-Myers Squibb Co has a 1 year low of $42.48 and a 1 year high of $66.99. The business has a fifty day moving average price of $62.32 and a two-hundred day moving average price of $52.93.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.17 earnings per share for the quarter, topping the consensus estimate of $1.06 by $0.11. The company had revenue of $6.01 billion during the quarter, compared to the consensus estimate of $5.89 billion. Bristol-Myers Squibb had a return on equity of 45.49% and a net margin of 23.53%. The firm’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.09 EPS. Sell-side analysts anticipate that Bristol-Myers Squibb Co will post 4.47 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd will be paid a dividend of $0.45 per share. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.41. The ex-dividend date is Thursday, January 2nd. This represents a $1.80 annualized dividend and a dividend yield of 2.71%. Bristol-Myers Squibb’s dividend payout ratio is presently 45.23%.

BMY has been the subject of a number of recent analyst reports. Morgan Stanley initiated coverage on Bristol-Myers Squibb in a research note on Friday, November 22nd. They issued an “equal weight” rating and a $60.00 price objective for the company. Bank of America initiated coverage on Bristol-Myers Squibb in a research note on Wednesday, October 16th. They issued a “buy” rating and a $60.00 price objective for the company. Argus upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $80.00 price objective for the company in a research note on Friday, December 13th. Wolfe Research set a $66.00 price objective on Bristol-Myers Squibb and gave the company a “buy” rating in a research note on Friday, November 1st. Finally, Citigroup upgraded Bristol-Myers Squibb from a “neutral” rating to a “buy” rating and set a $73.00 price objective for the company in a research note on Monday, January 6th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $61.69.

In other news, SVP John E. Elicker sold 15,000 shares of the stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $56.66, for a total transaction of $849,900.00. Following the completion of the transaction, the senior vice president now owns 74,471 shares in the company, valued at approximately $4,219,526.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Louis S. Schmukler sold 25,000 shares of the stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $56.56, for a total value of $1,414,000.00. Following the transaction, the insider now owns 31,963 shares of the company’s stock, valued at approximately $1,807,827.28. The disclosure for this sale can be found here. 0.13% of the stock is currently owned by corporate insiders.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Featured Story: What is the price-sales ratio?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.